Stockholders to Vote on Massive Dilution, Reverse Split to Avert Insolvency and Delisting
GOSS is trading near its 52-week low of $0.314 (1.9% below the low) on light trading volume (0.4× avg).
Summary
Gossamer Bio is seeking stockholder approval for a distressed debt exchange involving massive share dilution, a significant increase in authorized shares, and a reverse stock split, all critical measures to avoid insolvency and Nasdaq delisting.
Key Events · Financing and Capital Events · GOSS
-
Distressed Debt Exchange
The company is proposing an exchange offer for its outstanding $200 million convertible notes, replacing them with up to $72 million in new 7.50% Convertible Senior Secured First Lien Notes due 2030 and up to 317,647,058 shares of common stock.
-
Massive Share Dilution
The initial exchange will result in approximately 135% dilution for existing shareholders. If all new convertible notes fully convert, existing shareholders face potential dilution of up to 370% from the original outstanding shares.
-
Authorized Share Increase
Stockholders will vote to increase the authorized common stock from 700,000,000 to 4,000,000,000 shares to support the new issuances from the debt exchange and future equity incentive grants.
-
Reverse Stock Split Proposal
The Board seeks authority to effect a reverse stock split at a ratio between 1-for-10 and 1-for-150 to regain compliance with Nasdaq's minimum $1.00 bid price requirement, following a delisting notice received on April 8, 2026.
Analysis · GOSS · Life Sciences
This preliminary proxy statement details critical proposals for a special stockholder meeting, outlining the company's plan to address severe financial distress, a going concern warning, and a Nasdaq delisting notice. The core of the plan is a distressed debt exchange that will result in immediate and substantial dilution for existing shareholders, with potential for further dilution upon conversion of new notes. To facilitate this, the company needs to significantly increase its authorized share count. Additionally, a reverse stock split is proposed to regain Nasdaq compliance. Failure to approve these measures could lead to insolvency or bankruptcy, making these votes crucial for the company's continued operation.
At the time of this filing, GOSS was trading at $0.31 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $79.8M. The 52-week trading range was $0.31 to $3.87. This filing was assessed with negative market sentiment and an importance score of 9 out of 10.